Clinical Trial Update: Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of bortezomib and tipifarnib for relapsed or refractory multiple myeloma; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)
• ZARNESTRA

Snippet

Sponsor: Emory University | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED